Back

Should we rechallenge immune checkpoint inhibitors after myocarditis?

19 June 2026 (09:45 - 10:00)
Organised by: Logo
Congress Presentation Part of: Tackling challenging problems with expert answers Management of Cardiovascular Disease in Patients with Cancer Open Access ESC Cardio-Oncology 2026 Council of Cardio-Oncology

About the speaker

Photo
Professor Joe Elie Salem

Sorbonne University, Paris (France)

3 More presentations in this session

Presentation thumbnail
Permissive cardiotoxicity – how low can you go?
Doctor W. Meijers (Rotterdam, NL)
Slides
Presentation thumbnail
Fluoropyrimidine-induced cardiovascular toxicity – what is new?
Professor C. Manisty (London, GB)
Slides
Presentation thumbnail
Clinical case management: tackling challenging problems with expert answers - discussion

Access the full session

Session thumbnail
Tackling challenging problems with expert answers
Video

The Event

Event poster

ESC Cardio-Oncology 2026

19 June 2026 09:45 CET
You may be interested in
thumbnail
Congress Presentation
Immune checkpoint inhibitor-associated myocarditis: clinical characteristics, management, and outcomes from a tertiary cardio-oncology unit
21 June 2025
thumbnail
Webinar
How to manage cancer therapy-related cardiovascular toxicity. ESC 2022 Clinical Practice Guidelines - Webinar Series
19 September 2022
thumbnail
Congress Presentation
New insights into cancer therapy-related cardiac dysfunction - discussion
18 May 2025
thumbnail
Congress Session
The many faces of myocarditis
19 May 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources